<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:59:02 -0700</creation_date>
  <update_date>2013-01-15 19:59:02 -0700</update_date>
  <accession>HMDBP07435</accession>
  <secondary_accessions>
    <accession>13143</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Alpha-1A adrenergic receptor</synonym>
    <synonym>Alpha-1D adrenoceptor</synonym>
    <synonym>Alpha-1D adrenoreceptor</synonym>
    <synonym>Alpha-adrenergic receptor 1a</synonym>
  </synonyms>
  <gene_name>ADRA1D</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14443</accession>
      <name>Dapiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14490</accession>
      <name>Alfuzosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14600</accession>
      <name>Prazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14728</accession>
      <name>Doxazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14844</accession>
      <name>Tamsulosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14915</accession>
      <name>Propiomazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15293</accession>
      <name>Terazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15618</accession>
      <name>Sertindole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15627</accession>
      <name>Droxidopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15640</accession>
      <name>Xylometazoline</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha1-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:2</chromosome_location>
    <locus>20p13</locus>
    <gene_sequence>&gt;1719 bp
ATGACTTTCCGCGATCTCCTGAGCGTCAGTTTCGAGGGACCCCGCCCGGACAGCAGCGCA
GGGGGCTCCAGCGCGGGCGGCGGCGGGGGCAGCGCGGGCGGCGCGGCCCCCTCGGAGGGC
CCGGCGGTGGGCGGCGTGCCGGGGGGCGCGGGCGGCGGCGGCGGCGTGGTGGGCGCAGGC
AGCGGCGAGGACAACCGGAGCTCCGCGGGGGAGCCGGGGAGCGCGGGCGCGGGCGGCGAC
GTGAATGGCACGGCGGCCGTCGGGGGACTGGTGGTGAGCGCGCAGGGCGTGGGCGTGGGC
GTCTTCCTGGCAGCCTTCATCCTTATGGCCGTGGCAGGTAACCTGCTTGTCATCCTCTCA
GTGGCCTGCAACCGCCACCTGCAGACCGTCACCAACTATTTCATCGTGAACCTGGCCGTG
GCCGACCTGCTGCTGAGCGCCACCGTACTGCCCTTCTCGGCCACCATGGAGGTTCTGGGC
TTCTGGGCCTTTGGCCGCGCCTTCTGCGACGTATGGGCCGCCGTGGACGTGCTGTGCTGC
ACGGCCTCCATCCTCAGCCTCTGCACCATCTCCGTGGACCGGTACGTGGGCGTGCGCCAC
TCACTCAAGTACCCAGCCATCATGACCGAGCGCAAGGCGGCCGCCATCCTGGCCCTGCTC
TGGGTCGTAGCCCTGGTGGTGTCCGTAGGGCCCCTGCTGGGCTGGAAGGAGCCCGTGCCC
CCTGACGAGCGCTTCTGCGGTATCACCGAGGAGGCGGGCTACGCTGTCTTCTCCTCCGTG
TGCTCCTTCTACCTGCCCATGGCGGTCATCGTGGTCATGTACTGCCGCGTGTACGTGGTC
GCGCGCAGCACCACGCGCAGCCTCGAGGCGGGCGTCAAGCGCGAGCGAGGCAAGGCCTCC
GAGGTGGTGCTGCGCATCCACTGTCGCGGCGCGGCCACGGGCGCCGACGGGGCGCACGGC
ATGCGCAGCGCCAAGGGCCACACCTTCCGCAGCTCGCTCTCCGTGCGCCTGCTCAAGTTC
TCCCGTGAGAAGAAAGCGGCCAAGACTCTGGCCATCGTCGTGGGTGTCTTCGTGCTCTGC
TGGTTCCCTTTCTTCTTTGTCCTGCCGCTCGGCTCCTTGTTCCCGCAGCTGAAGCCATCG
GAGGGCGTCTTCAAGGTCATCTTCTGGCTCGGCTACTTCAACAGCTGCGTGAACCCGCTC
ATCTACCCCTGTTCCAGCCGCGAGTTCAAGCGCGCCTTCCTCCGTCTCCTGCGCTGCCAG
TGCCGTCGTCGCCGGCGCCGCCGCCCTCTCTGGCGTGTCTACGGCCACCACTGGCGGGCC
TCCACCAGCGGCCTGCGCCAGGACTGCGCCCCGAGTTCGGGCGACGCGCCCCCCGGAGCG
CCGCTGGCCCTCACCGCGCTCCCCGACCCCGACCCCGAACCCCCAGGCACGCCCGAGATG
CAGGCTCCGGTCGCCAGCCGTCGAAAGCCACCCAGCGCCTTCCGCGAGTGGAGGCTGCTG
GGGCCGTTCCGGAGACCCACGACCCAGCTGCGCGCCAAAGTCTCCAGCCTGTCGCACAAG
ATCCGCGCCGGGGGCGCGCAGCGCGCAGAGGCAGCGTGCGCCCAGCGCTCAGAGGTGGAG
GCTGTGTCCCTAGGCGTCCCACACGAGGTGGCCGAGGGCGCCACCTGCCAGGCCTACGAA
TTGGCCGACTACAGCAACCTACGGGAGACCGATATTTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>572</residue_number>
    <molecular_weight>60462.2</molecular_weight>
    <theoretical_pi>9.44</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>96-121</region>
      <region>134-159</region>
      <region>170-192</region>
      <region>214-238</region>
      <region>252-275</region>
      <region>349-373</region>
      <region>381-405</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Alpha-1D adrenergic receptor
MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGAGGGGGVVGAG
SGEDNRSSAGEPGSAGAGGDVNGTAAVGGLVVSAQGVGVGVFLAAFILMAVAGNLLVILS
VACNRHLQTVTNYFIVNLAVADLLLSATVLPFSATMEVLGFWAFGRAFCDVWAAVDVLCC
TASILSLCTISVDRYVGVRHSLKYPAIMTERKAAAILALLWVVALVVSVGPLLGWKEPVP
PDERFCGITEEAGYAVFSSVCSFYLPMAVIVVMYCRVYVVARSTTRSLEAGVKRERGKAS
EVVLRIHCRGAATGADGAHGMRSAKGHTFRSSLSVRLLKFSREKKAAKTLAIVVGVFVLC
WFPFFFVLPLGSLFPQLKPSEGVFKVIFWLGYFNSCVNPLIYPCSSREFKRAFLRLLRCQ
CRRRRRRRPLWRVYGHHWRASTSGLRQDCAPSSGDAPPGAPLALTALPDPDPEPPGTPEM
QAPVASRRKPPSAFREWRLLGPFRRPTTQLRAKVSSLSHKIRAGGAQRAEAACAQRSEVE
AVSLGVPHEVAEGATCQAYELADYSNLRETDI</protein_sequence>
  </protein_properties>
  <genbank_protein_id>56204084</genbank_protein_id>
  <uniprot_id>P25100</uniprot_id>
  <uniprot_name>ADA1D_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AL121675</genbank_gene_id>
  <genecard_id>ADRA1D</genecard_id>
  <geneatlas_id>ADRA1D</geneatlas_id>
  <hgnc_id>HGNC:280</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Bruno JF, Whittaker J, Song JF, Berelowitz M: Molecular cloning and sequencing of a cDNA encoding a human alpha 1A adrenergic receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1485-90.</reference_text>
      <pubmed_id>1656955</pubmed_id>
    </reference>
    <reference>
      <reference_text>Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.</reference_text>
      <pubmed_id>8183249</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.</reference_text>
      <pubmed_id>7815325</pubmed_id>
    </reference>
    <reference>
      <reference_text>Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.</reference_text>
      <pubmed_id>8024574</pubmed_id>
    </reference>
    <reference>
      <reference_text>Esbenshade TA, Hirasawa A, Tsujimoto G, Tanaka T, Yano J, Minneman KP, Murphy TJ: Cloning of the human alpha 1d-adrenergic receptor and inducible expression of three human subtypes in SK-N-MC cells. Mol Pharmacol. 1995 May;47(5):977-85.</reference_text>
      <pubmed_id>7746284</pubmed_id>
    </reference>
    <reference>
      <reference_text>Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20.  Nature. 2001 Dec 20-27;414(6866):865-71.</reference_text>
      <pubmed_id>11780052</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dapiprazole</name>
        <accession>HMDB14443</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dapiprazole</name>
        <accession>HMDB14443</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8.</reference_text>
        <pubmed_id>8799556</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity.  Prostate. 1997 Feb 15;30(3):202-15.</reference_text>
        <pubmed_id>9122046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13.</reference_text>
        <pubmed_id>15639685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605.</reference_text>
        <pubmed_id>8196478</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>McVary KT: BPH: epidemiology and comorbidities.  Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8.</reference_text>
        <pubmed_id>16613526</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96.</reference_text>
        <pubmed_id>16553574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4.</reference_text>
        <pubmed_id>11750253</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Cleary L, Slattery J, Bexis S, Docherty JR: Sympathectomy reveals alpha 1A- and alpha 1D-adrenoceptor components to contractions to noradrenaline in rat vas deferens. Br J Pharmacol. 2004 Nov;143(6):745-52. Epub 2004 Sep 27.</reference_text>
        <pubmed_id>15451776</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Kenny BA, Chalmers DH, Philpott PC, Naylor AM: Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol. 1995 Jul;115(6):981-6.</reference_text>
        <pubmed_id>7582530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Testa R, Destefani C, Guarneri L, Poggesi E, Simonazzi I, Taddei C, Leonardi A: The alpha 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci. 1995;57(13):PL159-63.</reference_text>
        <pubmed_id>7674815</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Bishop MJ: Recent advances in the discovery of alpha1-adrenoceptor agonists.  Curr Top Med Chem. 2007;7(2):135-45.</reference_text>
        <pubmed_id>17266602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Gilsbach R, Hein L: Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol. 2008;(184):261-88.</reference_text>
        <pubmed_id>18064417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Nagaoka Y, Ahmed M, Hossain M, Bhuiyan MA, Ishiguro M, Nakamura T, Watanabe M, Nagatomo T: Amino acids of the human alpha1d-adrenergic receptor involved in antagonist binding. J Pharmacol Sci. 2008 Jan;106(1):114-20. Epub 2008 Jan 11.</reference_text>
        <pubmed_id>18187928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Yamamoto Y, Koike K: alpha(1)-Adrenoceptor subtypes in the mouse mesenteric artery and abdominal aorta. Br J Pharmacol. 2001 Nov;134(5):1045-54.</reference_text>
        <pubmed_id>11682453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. Epub 2010 Apr 2.</reference_text>
        <pubmed_id>20363235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia.  Rev Urol. 2007 Fall;9(4):181-90.</reference_text>
        <pubmed_id>18231614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia.  Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.</reference_text>
        <pubmed_id>19002123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology.  Am Heart J. 2006 Nov;152(5):842-50.</reference_text>
        <pubmed_id>17070143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists.  Eur Urol. 1999;36 Suppl 1:35-41; discussion 65.</reference_text>
        <pubmed_id>10393471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.</reference_text>
        <pubmed_id>2981533</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8.</reference_text>
        <pubmed_id>18066532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchyiuma T, Korstanje C, Chapple CR: The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes. Br J Pharmacol. 1997 Jan;120(2):231-8.</reference_text>
        <pubmed_id>9117115</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Lowe FC: Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 4:S13-21.</reference_text>
        <pubmed_id>16986050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Tomiyama Y, Tatemichi S, Tadachi M, Kobayashi S, Hayashi M, Kobayashi M, Yamazaki Y, Shibata N: [Effect of silodosin on intraurethral pressure increase induced by hypogastric nerve stimulation in dogs with benign prostatic hyperplasia]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:225-30.</reference_text>
        <pubmed_id>16518087</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Ishiguro M, Futabayashi Y, Ohnuki T, Ahmed M, Muramatsu I, Nagatomo T: Identification of binding sites of prazosin, tamsulosin and KMD-3213 with alpha(1)-adrenergic receptor subtypes by molecular modeling. Life Sci. 2002 Oct 11;71(21):2531-41.</reference_text>
        <pubmed_id>12270758</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Taguchi K, Saitoh M, Sato S, Asano M, Michel MC: Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes.  J Pharmacol Exp Ther. 1997 Jan;280(1):1-5.</reference_text>
        <pubmed_id>8996174</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases.  Expert Opin Pharmacother. 2004 Jan;5(1):151-60.</reference_text>
        <pubmed_id>14680444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38.</reference_text>
        <pubmed_id>19179941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102.</reference_text>
        <pubmed_id>6086881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine.  Curr Med Res Opin. 2004 Dec;20(12):1877-81.</reference_text>
        <pubmed_id>15701205</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9.</reference_text>
        <pubmed_id>2870716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sertindole</name>
        <accession>HMDB15618</accession>
      </metabolite>
      <reference>
        <reference_text>Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia.  Expert Opin Pharmacother. 2006 Sep;7(13):1825-34.</reference_text>
        <pubmed_id>16925508</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Bishop MJ: Recent advances in the discovery of alpha1-adrenoceptor agonists.  Curr Top Med Chem. 2007;7(2):135-45.</reference_text>
        <pubmed_id>17266602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Du L, Li M: Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists. Curr Comput Aided Drug Des. 2010 Sep;6(3):165-78.</reference_text>
        <pubmed_id>20412040</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Kenny BA, Chalmers DH, Philpott PC, Naylor AM: Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol. 1995 Jul;115(6):981-6.</reference_text>
        <pubmed_id>7582530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Testa R, Destefani C, Guarneri L, Poggesi E, Simonazzi I, Taddei C, Leonardi A: The alpha 1d-adrenoceptor subtype is involved in the noradrenaline-induced contractions of rat aorta. Life Sci. 1995;57(13):PL159-63.</reference_text>
        <pubmed_id>7674815</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Xylometazoline</name>
        <accession>HMDB15640</accession>
      </metabolite>
      <reference>
        <reference_text>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline.  Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi:       10.1111/j.1472-8206.2009.00805.x.</reference_text>
        <pubmed_id>20030735</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
